MannKind Corp (MNKD) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Expansions ... [Yahoo! Finance]
MannKind Corporation (MNKD)
Last mannkind corporation earnings: 2/25 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.mannkindcorp.com/press-releases
Company Research
Source: Yahoo! Finance
For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points MannKind Corp ( NASDAQ:MNKD ) delivered a record revenue quarter of $82 million, driven by strong performance from Tyvaso DPI. The acquisition of SC Pharmaceuticals is expected to strengthen MannKind Corp's portfolio and enhance commercial scale. Afrezza showed significant growth, with a 31% increase in new prescriptions and a 23% rise in net revenue year over year. The company is advancing its pipeline with the acceptance of Fred's supplemental BLA for review and the submission of SNDA for the 406 autoinjector. MannKind Corp is expanding its focus into cardio renal medicine with the addition of Firoix, addressing significant unmet needs in heart failure and CKD. Negative Points Despite revenue growth, MannKind Corp's GAAP net income decreased to $8 million from $11.6 million in the prior year. The shift in focus to type 1 diabetes has led to a decline
Show less
Read more
Impact Snapshot
Event Time:
MNKD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNKD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNKD alerts
High impacting MannKind Corporation news events
Weekly update
A roundup of the hottest topics
MNKD
News
- Reassessing MannKind (MNKD) Valuation After Recent Share Price Reset [Yahoo! Finance]Yahoo! Finance
- MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney DiseaseGlobeNewswire
- MannKind (NASDAQ:MNKD) was given a new $9.00 price target on by analysts at Truist Financial Corporation.MarketBeat
- MannKind (NASDAQ:MNKD) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.MarketBeat
- MannKind (NASDAQ:MNKD) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $7.00 price target on the stock.MarketBeat
MNKD
Earnings
- 11/5/25 - Beat
MNKD
Sec Filings
- 12/4/25 - Form 4
- 12/4/25 - Form 4
- 12/2/25 - Form 144
- MNKD's page on the SEC website